Nykode Therapeutics ASA (NYKD): key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2024)
- $8.7M
- Net Income/Loss (FY2024)
- -$38.8M
- Total Assets (FY2024)
- $153.5M
- Total Equity (FY2024)
- $136.2M
- Cash Flows from Operating Activities (FY2024)
- -$51.2M
Source: Nykode Therapeutics ASA annual_report filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
